Neurology News and Research RSS Feed - Neurology News and Research

Dr. Mike O. Karl awarded EYEnovative Research Award for retina research

Dr. Mike O. Karl awarded EYEnovative Research Award for retina research

Dr. Mike O. Karl, group leader at the German Center for Neurodegenerative Diseases and the DFG Research Center for Regenerative Therapies Dresden - Cluster of Excellence at the TU Dresden, was awarded the “EYEnovative Förderpreis” of the Novartis Pharma GmbH already for the second time. [More]
New study shows 'alarming rise' in costs of MS drugs over last 20 years

New study shows 'alarming rise' in costs of MS drugs over last 20 years

A new study shows an "alarming rise" over the last 20 years in the costs of drugs used to slow the progression of multiple sclerosis or reduce the frequency of attacks, according to a study led by researchers at Oregon Health & Science University and Oregon State University. [More]
Loyola's study on simulated stroke earns prestigious 2015 Safety and Quality Award

Loyola's study on simulated stroke earns prestigious 2015 Safety and Quality Award

A study performed by Loyola University Medical Center resident neurologists has won a prestigious 2015 Safety and Quality Award from the American Academy of Neurology. [More]
Positive CHMP opinion recommends RELISTOR for treatment of opioid-induced constipation

Positive CHMP opinion recommends RELISTOR for treatment of opioid-induced constipation

Valeant Pharmaceuticals International, Inc. and Progenics Pharmaceuticals, Inc. today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending a new indication for RELISTOR (methylnaltrexone bromide) Subcutaneous Injection for the treatment of opioid-induced constipation (OIC) when response to laxative therapy has not been sufficient in adult patients, aged 18 years and older. [More]
Study: Long-term exposure to air pollution can damage brain structures, impair cognitive function

Study: Long-term exposure to air pollution can damage brain structures, impair cognitive function

Air pollution, even at moderate levels, has long been recognized as a factor in raising the risk of stroke. A new study led by scientists from Beth Israel Deaconess Medical Center and Boston University School of Medicine suggests that long-term exposure can cause damage to brain structures and impair cognitive function in middle-aged and older adults. [More]
Case Western Reserve and MIT receive $1.7 million to explore potential treatments for Down syndrome

Case Western Reserve and MIT receive $1.7 million to explore potential treatments for Down syndrome

Thanks to the generosity of a philanthropy dedicated to children's issues, renowned Down syndrome researcher Alberto Costa, MD, PhD, has taken yet another step toward making Northeast Ohio the nation's leader in exploring potential treatments of the genetic condition that affects 400,000 people in the U.S. [More]
Study: Demanding jobs raise survival chances in frontotemporal dementia

Study: Demanding jobs raise survival chances in frontotemporal dementia

People with more demanding jobs may live longer after developing the disease frontotemporal dementia than people with less skilled jobs, according to a new study published in the April 22, 2015, online issue of Neurology, the medical journal of the American Academy of Neurology. [More]
Gulf Coast residents continue to struggle with the aftermath of Deepwater Horizon oil spill

Gulf Coast residents continue to struggle with the aftermath of Deepwater Horizon oil spill

Five years ago, on April 20, 2010, the BP Deepwater Horizon oil platform exploded; over the next five months, more than 206 million gallons of oil gushed into the Gulf of Mexico, affecting more than 950 miles of shoreline. [More]
New brain mapping model could improve success rate of transcranial magnetic stimulation

New brain mapping model could improve success rate of transcranial magnetic stimulation

Brain researchers from the Perelman School of Medicine at the University of Pennsylvania have developed a new brain mapping model which could improve the success rate of transcranial magnetic stimulation (TMS) in treating conditions including depression, neuropathic pain, and stroke. [More]
UC San Diego, Scripps partner to improve patient care, physician training and research in hospice medicine

UC San Diego, Scripps partner to improve patient care, physician training and research in hospice medicine

UC San Diego Health System and Scripps Health are partnering to provide improved continuity of patient care, fellowship training and research in hospice and palliative medicine. Under a new five-year agreement, Scripps will work with UC San Diego to provide outpatient and inpatient hospice care for UC San Diego patients, allowing UC San Diego physicians to better coordinate post-acute care for patients with chronic illness. [More]
New treatment shows promise in easing symptoms of Parkinson's disease

New treatment shows promise in easing symptoms of Parkinson's disease

To date, a cure for Parkinson's disease remains elusive for the more than 50,000 Americans diagnosed yearly, despite decades of intensive study. But a newly approved treatment that might help ease the symptoms of Parkinson's has shown remarkable promise. [More]
New research examines what happens when MS patients discontinue their medication

New research examines what happens when MS patients discontinue their medication

New research led by NYU Langone Medical Center examines what happens when a patient with multiple sclerosis (MS) who is clinically stable stops taking their medication. [More]
Astellas, Potenza collaborate to develop immuno-oncology therapeutics for patients with certain cancers

Astellas, Potenza collaborate to develop immuno-oncology therapeutics for patients with certain cancers

Astellas Pharma Inc. and Potenza Therapeutics, Inc., a biotechnology company developing a portfolio of immuno-oncology programs, today announced an exclusive research and development collaboration. [More]
Upsher-Smith presents favorable data from PREVAIL OLE study of Qudexy XR capsules

Upsher-Smith presents favorable data from PREVAIL OLE study of Qudexy XR capsules

Upsher-Smith Laboratories, Inc. presented data from a 52-week, open-label extension study (PREVAIL OLE) showing that Qudexy XR (topiramate) extended-release capsules offered a long-term adjunctive treatment option with a favorable tolerability profile for a high proportion of patients with refractory partial-onset seizures (POS). [More]
BrainStorm presents positive results from NurOwn phase 2a study in ALS at AAN annual meeting

BrainStorm presents positive results from NurOwn phase 2a study in ALS at AAN annual meeting

BrainStorm Cell Therapeutics Inc., a leading developer of adult stem cell technologies for neurodegenerative diseases, is presenting results from its phase 2a study of NurOwn in amyotrophic lateral sclerosis (ALS) at a poster session today at the American Academy of Neurology annual meeting, taking place in Washington D.C. [More]
Montefiore and Einstein researchers to present new findings on neurological disorders at AAN 2015

Montefiore and Einstein researchers to present new findings on neurological disorders at AAN 2015

Researchers from Montefiore Health System and Albert Einstein College of Medicine will present new findings on how to effectively treat migraine, and forecast the onset of pain in a number of neurological conditions including dementia in older adults. [More]
UCLA-led stroke study selected as one of 10 most outstanding research papers by CRF

UCLA-led stroke study selected as one of 10 most outstanding research papers by CRF

A UCLA-led study on improving stroke care was selected by the Clinical Research Forum (CRF) as one of the 10 most outstanding research papers written by teams from across the nation in 2014. The organization highlighted the papers at its fourth annual awards ceremony in Washington, D.C. on April 16. [More]
Study: Extending natalizumab treatment effective in preventing MS symptoms

Study: Extending natalizumab treatment effective in preventing MS symptoms

In a study of 1,964 patients with multiple sclerosis (MS) led by researchers at the NYU Langone Multiple Sclerosis Comprehensive Care Center, extending the dose of natalizumab from 4 weeks up to 8 weeks was shown to be well-tolerated and effective in patients, and resulted in no cases of the potentially fatal side effect progressive multifocal leukoencephalopathy (PML). [More]
Clinical trials show benefits of endovascular therapy for acute ischemic strokes

Clinical trials show benefits of endovascular therapy for acute ischemic strokes

Anthony J. Furlan, MD, Chairman of Neurology and Co-Director of the Neurological Institute at University Hospitals Case Medical Center and Case Western Reserve University School of Medicine, who writes an accompanying editorial for five studies about endovascular stroke therapy published simultaneously in the New England Journal of Medicine (NEJM.org">NEJM.org April 17), says these randomized clinical trials represent a breakthrough in showing the benefits of endovascular therapy for acute ischemic strokes. [More]
Study confirms benefits of removing blood clots after stroke

Study confirms benefits of removing blood clots after stroke

A technique that removes blood clots from large brain blood vessels reduced disability after stroke in a trial conducted in Catalonia, Spain, and co-led by an expert from the University of Pittsburgh School of Medicine. [More]
Advertisement